Rapid Diagnosis of XDR and Pre-XDR TB: A Systematic Review of Available Tools
Arch. bronconeumol. (Ed. impr.)
; 58(12): 809-820, dic. 2022. ilus, tab
Article
en En
| IBECS
| ID: ibc-213185
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Introduction: No previous systematic reviews have comprehensively investigated the features of Xpert MTB/XDR and other rapid tests to diagnose pre-XDR/XDR-TB. The aim of this systematic review is to assess existing rapid diagnostics for pre-XDR/XDR-TB from a point-of-care perspective and describe their technical characteristics (i.e., sensitivity, specificity, positive and negative predictive values). Methods: Embase, PubMed, Scopus, and Web of Science were searched to detect the articles focused on the accuracy of commercially available rapid molecular diagnostic tests for XDR-TB according to PRISMA guidelines. The analysis compared the diagnostic techniques and approaches in terms of sensitivity, specificity, laboratory complexity, time to confirmed diagnosis. Results: Of 1298 records identified, after valuating article titles and abstracts, 97 (7.5%) records underwent full-text evaluation and 38 records met the inclusion criteria. Two rapid World Health Organization (WHO)-endorsed tests are available: Xpert MTB/XDR and GenoType MTBDRsl (VER1.0 and VER 2.0). Both tests had similar performance, slightly favouring Xpert, although only 2 studies were available (sensitivity 91.494; specificity 98.599; accuracy 97.297.7; PPV 88.999.1; NPV 95.898.9). Conclusions: Xpert MTB/XDR could be suggested at near-point-of-care settings to be used primarily as a follow-on test for laboratory-confirmed TB, complementing existing rapid tests detecting at least rifampicin-resistance. Both Xpert MTB/XDR and GenoType MTBDRsl are presently diagnosing what WHO defined, in 2021, as pre-XDR-TB. (AU)
Palabras clave
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Tuberculosis Resistente a Múltiples Medicamentos
/
Tuberculosis Extensivamente Resistente a Drogas
/
Mycobacterium tuberculosis
Límite:
Humans
Idioma:
En
Revista:
Arch. bronconeumol. (Ed. impr.)
Año:
2022
Tipo del documento:
Article